Insider Buying: Noxopharm Ltd (ASX:NOX) Insider Acquires 53,263 Shares of Stock

Noxopharm Ltd (ASX:NOX) insider Graham Kelly bought 53,263 shares of the firm’s stock in a transaction on Tuesday, September 10th. The shares were bought at an average cost of A$0.36 ($0.25) per share, for a total transaction of A$19,068.15 ($13,523.51).

Shares of ASX NOX remained flat at $A$0.38 ($0.27) during midday trading on Thursday. 332,402 shares of the company’s stock were exchanged. The company’s 50 day moving average price is A$0.43 and its 200-day moving average price is A$0.47. The stock has a market capitalization of $47.30 million and a PE ratio of -4.08. Noxopharm Ltd has a 12-month low of A$0.35 ($0.24) and a 12-month high of A$0.76 ($0.54). The company has a current ratio of 0.68, a quick ratio of 0.53 and a debt-to-equity ratio of 56.87.

Noxopharm Company Profile

Noxopharm Limited, a drug development company, focuses on the research and development of drugs to enhance radiotherapy in Australia and internationally. It is developing Veyonda, a dosage formulation of idronoxil, a generic anti-cancer agent for the treatment of late-stage cancers. The company also focuses on developing NYX-104, a drug intended to protect the brain from excitotoxicity; NYX-205, a drug to treat inflammation of the nervous tissue; and NYX-330, a PCSK9-inhibitor developed as a companion product for statin drugs in lowering low density lipoprotein cholesterol levels in patients at risk of cardiovascular disease.

Featured Story: How to Trade Using Analysts Ratings

Receive News & Ratings for Noxopharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Noxopharm and related companies with MarketBeat.com's FREE daily email newsletter.